文献速递类风湿关节炎其他结缔组织病

生物制剂与靶向合成DMARD与类风湿关节炎相关间质性肺病死亡率的真实世界关联:全国队列研究

Real-world association of biologic and targeted synthetic DMARD use with mortality in rheumatoid arthritis-associated interstitial lung disease: a nationwide cohort study.
PubMed 文献 · RMD Open · 2026-10-23

该全国队列研究纳入2010至2021年新诊断的6292例RA-ILD患者,比较使用b/tsDMARD与仅用csDMARD的全因及病因特异性死亡率。经IPTW调整后,b/tsDMARD使用与较低的全因死亡率(HR 0.75,95%CI 0.62-0.89)、呼吸相关死亡率(sHR 0.72,95%CI 0.56-0.91)及ILD相关死亡率(sHR 0.63,95%CI 0.43-0.88)相关;心血管、癌症及感染相关死亡率无显著关联。

要点

  • b/tsDMARD使用与呼吸相关及ILD相关死亡风险降低相关。
  • TNF抑制剂、阿巴西普、托珠单抗和JAK抑制剂与全因死亡率降低相关。

核心结论

  • b/tsDMARD使用与RA-ILD患者较低的全因死亡率和呼吸相关死亡率相关。

研究设计与样本

  • 基于全国健康保险数据库的队列研究,纳入2010至2021年新诊断的6292例RA-ILD患者。
  • b/tsDMARD使用作为时依暴露,采用IPTW平衡基线协变量。
  • 全因死亡率用时依Cox模型分析,病因特异性死亡率用时依Fine-Grey竞争风险模型分析。

主要发现

  • 随访期间1074例接受b/tsDMARD,5218例仅接受csDMARD,共发生1964例死亡。
  • IPTW后b/tsDMARD使用与较低全因死亡率相关(HR 0.75,95%CI 0.62-0.89)。
  • b/tsDMARD使用与较低呼吸相关死亡率(sHR 0.72,95%CI 0.56-0.91)及ILD相关死亡率(sHR 0.63,95%CI 0.43-0.88)相关。
  • 心血管、癌症及感染相关死亡率无统计学显著关联。
  • 全因死亡率HR:TNF抑制剂0.61(95%CI 0.44-0.86),阿巴西普0.71(95%CI 0.53-0.9),托珠单抗0.68(95%CI 0.52-0.89),利妥昔单抗0.76(95%CI 0.28-2.06),JAK抑制剂0.61(95%CI 0.39-0.95)。

临床怎么用

  • 在RA-ILD患者中,b/tsDMARD使用与死亡风险降低相关,支持对该人群考虑b/tsDMARD治疗。

局限性

  • 需结合临床、肺功能及影像学数据的进一步研究确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the association between biologic and targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) use and all-cause mortality and cause-specific mortality in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). METHODS: We identified patients with incident RA-ILD between 2010 and 2021 using the National Health Insurance database. The index date was the date of RA-ILD diagnosis, and subsequent b/tsDMARD use was treated as time-dependent exposure. Inverse probability of treatment weighting (IPTW) was used to balance measured baseline covariates. All-cause mortality was analysed using time-dependent Cox proportional hazards models and cause-specific mortality using time-dependent Fine–Grey competing-risk models. RESULTS: Among 6292 patients with RA-ILD, 1074 received b/tsDMARD during follow-up and 5218 received conventional synthetic DMARDs only. 1964 deaths occurred. After IPTW, b/tsDMARD use was associated with lower all-cause mortality (HR 0.75, 95% CI 0.62 to 0.89), respiratory-related mortality (subdistribution HR (sHR) 0.72, 95% CI 0.56 to 0.91) and ILD-related mortality nested within respiratory mortality (sHR 0.63, 95% CI 0.43 to 0.88). No statistically significant associations were observed for cardiovascular, cancer-related or infection-related mortality. In class-specific analyses, HRs for all-cause mortality versus non-b/tsDMARDs were 0.61 (95% CI 0.44 to 0.86) for tumour necrosis factor inhibitors, 0.71 (0.53 to 0.9) for abatacept, 0.68 (0.52 to 0.89) for tocilizumab, 0.76 (0.28 to 2.06) for rituximab and 0.61 (0.39 to 0.95) for Janus kinase inhibitors. CONCLUSIONS: b/tsDMARD use was associated with lower all-cause mortality and respiratory-related mortality in patients with RA-ILD. Further studies incorporating clinical, pulmonary function and radiological data are needed to confirm these findings.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Joo YB, Ryu S, Go J, et al. Real-world association of biologic and targeted synthetic DMARD use with mortality in rheumatoid arthritis-associated interstitial lung disease: a nationwide cohort study. RMD Open. 2026. PMID: 42919618. doi:10.1136/rmdopen-2026-007179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。